Cargando…

Bruton's Agammaglobulinemia and COVID-19

During the SARS-CoV-2 global pandemic, many patients who have co-morbid conditions are considered high risk for morbidity and mortality; however, those who are immunodeficient are at higher risk of becoming seriously ill. In this article, we present a 26-year old male with a history of X-linked agam...

Descripción completa

Detalles Bibliográficos
Autores principales: Hovey, Justin G, Tolbert, Denise, Howell, Druhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769814/
https://www.ncbi.nlm.nih.gov/pubmed/33391934
http://dx.doi.org/10.7759/cureus.11701
_version_ 1783629409088962560
author Hovey, Justin G
Tolbert, Denise
Howell, Druhan
author_facet Hovey, Justin G
Tolbert, Denise
Howell, Druhan
author_sort Hovey, Justin G
collection PubMed
description During the SARS-CoV-2 global pandemic, many patients who have co-morbid conditions are considered high risk for morbidity and mortality; however, those who are immunodeficient are at higher risk of becoming seriously ill. In this article, we present a 26-year old male with a history of X-linked agammaglobulinemia who presented to the hospital with fever and chills after exposure to a SARS-CoV-2 positive individual. The patient had a prolonged course in the hospital, but his symptoms improved quickly after receiving convalescent plasma. This case highlights the clinical course of a patient with severe immunoglobulin deficiency and a possible treatment approach for patients with concomitant agammaglobulinemia and COVID-19.
format Online
Article
Text
id pubmed-7769814
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-77698142020-12-31 Bruton's Agammaglobulinemia and COVID-19 Hovey, Justin G Tolbert, Denise Howell, Druhan Cureus Internal Medicine During the SARS-CoV-2 global pandemic, many patients who have co-morbid conditions are considered high risk for morbidity and mortality; however, those who are immunodeficient are at higher risk of becoming seriously ill. In this article, we present a 26-year old male with a history of X-linked agammaglobulinemia who presented to the hospital with fever and chills after exposure to a SARS-CoV-2 positive individual. The patient had a prolonged course in the hospital, but his symptoms improved quickly after receiving convalescent plasma. This case highlights the clinical course of a patient with severe immunoglobulin deficiency and a possible treatment approach for patients with concomitant agammaglobulinemia and COVID-19. Cureus 2020-11-25 /pmc/articles/PMC7769814/ /pubmed/33391934 http://dx.doi.org/10.7759/cureus.11701 Text en Copyright © 2020, Hovey et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Hovey, Justin G
Tolbert, Denise
Howell, Druhan
Bruton's Agammaglobulinemia and COVID-19
title Bruton's Agammaglobulinemia and COVID-19
title_full Bruton's Agammaglobulinemia and COVID-19
title_fullStr Bruton's Agammaglobulinemia and COVID-19
title_full_unstemmed Bruton's Agammaglobulinemia and COVID-19
title_short Bruton's Agammaglobulinemia and COVID-19
title_sort bruton's agammaglobulinemia and covid-19
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769814/
https://www.ncbi.nlm.nih.gov/pubmed/33391934
http://dx.doi.org/10.7759/cureus.11701
work_keys_str_mv AT hoveyjusting brutonsagammaglobulinemiaandcovid19
AT tolbertdenise brutonsagammaglobulinemiaandcovid19
AT howelldruhan brutonsagammaglobulinemiaandcovid19